NEO patients | pPR (n = 3) |
P
| pCR (n = 12) |
P
|
P
c
|
|---|
Cytotoxicity | Cytotoxicity |
|---|
BASAL
|
ADCC
|
BASAL
|
ADCC
|
|---|
SKBR3
| n = 3 | n = 3 | | n = 11 | n = 11 | | |
Present | 1 (33.3) | 3 (100.0) | 0.400 | 4 (36.4) | 9 (81.8) | 0.080 | 0.240 |
Absent | 2 (66.7) | 0 (–) | | 7 (63.6) | 2 (18.2) | | |
BT474
| n = 2 | n = 2 | | n = 9 | n = 9 | | |
Present | 0 (–) | 1 (50.0) | 0.400 | 1 (11.1) | 6 (66.7) | 0.050 | 0.147 |
Absent | 2 (100.0) | 1 (50.0) | | 8 (88.9) | 3 (33.3) | | |
MCF-7
| n = 2 | n = 2 | | n = 11 | n = 11 | | |
Present | 0 (–) | 2 (100.0) | 0.333 | 2 (18.2) | 10 (90.9) | 0.002 | 0.006 |
Absent | 2 (100.0) | 0 (–) | | 9 (81.8) | 1 (9.1) | | |
- PBMCs were analyzed for their cytolytic activity in an ADCC assay using trastuzumab (2 µg/ml) and SKBR3, BT474 and MCF-7 cell lines at 20:1 effector to target cell ratio. PBMCs were incubated with target cells in medium alone (BASAL) or in the presence of trastuzumab (ADCC). Results are expressed as number and percentages (in brackets) of patients showing basal or trastuzumab-mediated cytotoxicity (cut off: >5 %)
- Comparison of BASAL cytotoxicity and ADCC was estimated using the Fisher’s test (P value) (significance level <0.05) and further adjusted with Bonferroni correction for multiple comparisons (P
c value) in the indicated patients
-
NEO neoadjuvant, ADCC antibody-dependent cellular cytotoxicity, pPR pathological partial response, pCR pathological complete response
